US2196322A - Pharmaceutical - Google Patents

Pharmaceutical Download PDF

Info

Publication number
US2196322A
US2196322A US178132A US17813237A US2196322A US 2196322 A US2196322 A US 2196322A US 178132 A US178132 A US 178132A US 17813237 A US17813237 A US 17813237A US 2196322 A US2196322 A US 2196322A
Authority
US
United States
Prior art keywords
inhalant
oil
ephedrine
essentially
ethyl oleate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US178132A
Inventor
Ferdinand W Nitardy
Walter G Christiansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Priority to US178132A priority Critical patent/US2196322A/en
Application granted granted Critical
Publication of US2196322A publication Critical patent/US2196322A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy

Description

Patented Apr. 9, 1940 UNITED STATES PATENT OFFICE PHARMACEUTICAL No Drawing.
Application December 4, 1937,
Serial No. 178,132
,9 Claims. (Cl. 16758) This invention relates to inhalan s, i. e., preparations for nasal administration, as by dropping or spraying.
Heretofore, oil-soluble inhalant medicinal agents (e. g., ephedrine) have been incorporated in mineral-oil vehicles for the production of inhalants. Numerous cases of lipoid pneumonia have resulted from the use of such preparations, apparently because of the non-absorption of oil vehicle finding its way' into the alveoli of the lung.
It is the object of this invention to provide non-injurious inhalants; more particularly, to provide preparations of oil-soluble inhalant ll medicinal agents embodying a vehicle absorbable by the lungs.
It has been found that certain oily aliphatic esters are absorbable by the body and constitute effective vehicles for oil-soluble inhalant medlcg0 inal agents. In the event these absorbable oily aliphatic esters enter the lung, they do not remain there, either because of their tendency to pass into water solution or because of their susceptibility to enzyme hydrolysis. Moreover, the 535 slight water-solubility of some of these esters enhances the effectiveness of the .medicinal agents, since aqueous fluids are present in the nasal passages.
The following esters, inter alia, have been found to be absorbable eifective vehicles:
Aliphatic polyhydroxy compounds completely 5 esterified with higher fatty acids, such as ,glyceryl' trioleate, remain unabsorbed in the lung. The
absorbable vehicles specifically disclosed belong to the group: consisting of lower-alkyl esters of 'higher fatty acids and aliphatic polyhydroxy compounds partially esterified with higher fatty acids;
These absorbable vehicles are eflective for all inhalants embodying oil-soluble medicinal agents.
The following examples are illustrative of the application of this invention to plain and compound ephedrine inhalants and to non-ephedrine inhalants.
Example 1 A plain ephedrine inhalant is made by incorporating 1.5 g. ephedrine in 148.5 g. ethyl oleate.
Example 2 A compound ephedrine inhalant is made by incorporating the following in 144.0 g. ethyl l0 I Example 3- A non-ephedrine inhalant is made by incorporating the following in 144.0- g. ethyl oleate:
Grams Phenol 1.1
Menthol 1.1 25
Example 4 An inhalant is made by incorporating p-phenethyl amine, p-phenyl-isopropylamine, m (or p) hYdIOXY-a- (methylaminomethyl) -benzyl alcohol,
or the like in ethyl oleate.
Example 5 p-phenethyl amine or amed cinal derivative thereof is incorporated in the compound inhalant preparation of Example 2 in place of ephedrine.
In the compound inhalants, a variety of substances can be used instead of the phenol, camphor, menthol, oil of thyme, and oil of lilac. Menthol and camphor are employed torelieve congestion, and oil of thyme and oil of lilac to improve the odor of the product; and these may be replaced by other similarly efiective agents. The phenol is used because of its anesthetic and antiseptic properties; and may be, replaced by anesthetics such as 'benzyl alcohol, saligenin, chlorobutanol, or the alkyl esters of para-amino- 50 benzoic acid, and/or by antiseptics such as hydroxy-quinoline, chlor-hydroxy-quinoline, or
ethyl butyl resorcinol.
When the inhalant is unsatisfactory because of excessive viscosity of the vehicle, adjustment can u be made by replacing part of the viscous vehicle with ethyl oleate. Conversely, if the ethyl oleate preparations are too thin, this vehicle may be partly replaced with one having a higher viscosity. i
The invention may be variously otherwise embodied within the scope of the appended claims.
We claim:
1. An inhalant essentially comprising an oilsoluble inhalant medicinal agent and a lungabsorbable vehicle of the group consisting of lower-alkyl esters of higher fatty acids and allphatic polyhydroxy compounds incompletely esterifled with higher fatty acids.
2. An inhalant essentially comprising an oil soluble inhalant medicinal agent and a lungabsorbable oily aliphatic mono-ester of a higher fatty acid. v
3. An inhalant essentially comprising an oil- 20 soluble inhalant medicinal agent and a lung'- absorbable oily aliphatic mono-ester of a higher unsaturated fatty acid.
4. An inhalant essentially comprising an oilsoluble inhalant medicinal agent and ethyl oleate.
5. An, inhalant essentially comprising an oilsoluble inhalant medicinal agent and an ethyl ester of the mixture of fatty acids derivable I from an oil of the group consisting of olive oil,
coconut oil, and linseed oil.
6. An inhalant essentially comprising an oilsoluble inhalant medicinal agent and glyceryl mono-oleate. i
7. An inhalant essentially comprising ephedrine and ethyl oleate.
8. An inhalant essentially comprising phenol, menthol, camphor, and ethyl oleate.
9.- A medicinal inhalant preparation essentially comprising p-phenethylamine and ethyl oleate.
FERDINAND W. NITARDY. WALTER G. CHRISTIANSEN.
US178132A 1937-12-04 1937-12-04 Pharmaceutical Expired - Lifetime US2196322A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US178132A US2196322A (en) 1937-12-04 1937-12-04 Pharmaceutical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US178132A US2196322A (en) 1937-12-04 1937-12-04 Pharmaceutical

Publications (1)

Publication Number Publication Date
US2196322A true US2196322A (en) 1940-04-09

Family

ID=22651333

Family Applications (1)

Application Number Title Priority Date Filing Date
US178132A Expired - Lifetime US2196322A (en) 1937-12-04 1937-12-04 Pharmaceutical

Country Status (1)

Country Link
US (1) US2196322A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0160501A2 (en) * 1984-04-25 1985-11-06 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
WO1992005781A1 (en) * 1990-09-28 1992-04-16 The Procter & Gamble Company Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0160501A2 (en) * 1984-04-25 1985-11-06 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
EP0160501A3 (en) * 1984-04-25 1986-12-30 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
WO1992005781A1 (en) * 1990-09-28 1992-04-16 The Procter & Gamble Company Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents

Similar Documents

Publication Publication Date Title
DE69231994T3 (en) Chlorofluorocarbon-free aerosol formulations
US5096916A (en) Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
AU724070B2 (en) Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
US4668513A (en) Method for combating snoring
DE69828817T2 (en) PHARMACEUTICAL AEROSOL COMPOSITIONS
PT1277467E (en) Non-chlorofluorocarbon aerosol formulations
US6156792A (en) Calcium mupirocin non-aqueous nasal spray for otitis media or for recurrent acute bacterial sinusitis
JP2017052804A (en) Ophthalmological aqueous composition
EP0243308A2 (en) Stabilization of the preservative Thiomersal in ophthalmic pharmaceutical compositions
JPS6036414A (en) Medicine for oral, nasal and pharyngal mucosa
US3232833A (en) Heparin containing compositions
DE202014105553U1 (en) Cineole-containing composition for nasal administration
US2196322A (en) Pharmaceutical
WO1983003544A1 (en) Perfluorohydrocarbons as vehicles for administering drugs
JP2017057145A (en) External composition
DE2611183C2 (en) Stabilized formulation of PGE-type prostaglandin-like drugs
IE51097B1 (en) Stable benzoyl peroxide compositions
DE3317530A1 (en) Antisnoring composition
ITMI20090829A1 (en) OPHTHALMIC COMPOSITIONS FOR THE REITITIZATION, CYCLING, AND DISINFECTION OF THE EYE FABRICS
CN103766339A (en) Composition containing trans-cinnamaldehyde
EP0680760A1 (en) Topical antipruritic composition containing a phosphonic acid diester compound
US3374144A (en) Ophthalmic composition
Dunn et al. A Mixture of High Molecular Alkyl-dimethyl-benzyl-ammonium Chlorides as an Antiseptic.
US2546895A (en) Aerial disinfectants and method of using the same
US5250286A (en) Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline